About this program
DateOctober 6, 2023 - November 10, 2023
PlaceLive sessions (via Zoom)
3 hours weekly
1 hour weekly
Price1250 CAD + tax
Through this 6-week program, you will learn how to approach problems using relevant readings and research, and how to apply this knowledge to psychedelic-assisted therapy using case-based learning. The cases will explore decision making regarding what medicine and psychotherapeutic approaches may be most appropriate in specific contexts. We will focus on four key indications: Mood and anxiety disorders, post-traumatic stress, addictive disorders, chronic and serious illnesses.
This program offers continuing professional development credits to registered professionals. A certificate with accreditation through the Canadian Psychological Association (CPA), l’Ordre des psychologues du Québec and the Canadian Counselling and Psychotherapy Association (CCPA) will be provided upon completion.
This course includes 18 hours of live sessions and 6 hours of online pre-work. It is offered in English by a team of instructors. Please see below for more information.
Fall 2023 Cohort: October
Time (PT): 9:00am-12:00pm PT
Time (ET): 12:00pm-3:00pm ET
Course access begins: Monday, September 25
First live session: Friday, October 6
Last live session: Friday, November 10
In order to register for this course, you must have:
Successfully completed the Fundamentals of Psychedelic-Assisted Therapy course
Experience with motivational interviewing
If you do not meet these prerequisites, please reach out to email@example.com for recommendations to support you.
Please use the arrows below to learn more about what will be taught in each module.
• Transdiagnostic perspectives
• Biases in the DSM
• Research Domain Criteria
• Describe the role of the DSM and ICD in the diagnosis of mental illness.
• Examine how the DSM has contributed to the oppression and marginalization of social groups on the basis of race, gender, and other social factors.
• Apply the Numinus care model to transdiagnostic approaches to mental health.
• Examine indication-based and transdiagnostic-based approaches to psychopathology.
• Critically evaluate the Research Domain Criteria as an alternative to the DSM model.
• Explain the transdiagnostic potential of psychedelic-assisted therapy.
• Psychedelic-assisted therapy for depression
• Anxiety-related disorders
• Shared transdiagnostic factors for anxiety and depression
• Psychedelic-assisted therapy for anxiety
• Identify which psychedelic medicines have been used for psychedelic-assisted therapy in the treatment of depression and anxiety.
• Describe key evidence-based literature supporting the use of psychedelic-assisted therapy in the treatment of anxiety and depression.
• Compare the DSM criteria and transdiagnostic factors of anxiety and depression.
• Justify the rationale for using a transdiagnostic approach to the treatment of anxiety and depression.
• Describe the similarities and differences between anxiety disorders and anxiety-related disorders such as obsessive-compulsive and related disorders and trauma- and stressor-related disorders.
• Transdiagnostic perspectives of post-traumatic stress
• Psychedelic-assisted therapy for post-traumatic stress
• Identify which psychedelic medicines have been used for psychedelic-assisted therapy in the treatment of post-traumatic stress.
• Describe key evidence-based literature supporting the use of psychedelic-assisted therapy in the treatment of post-traumatic stress.
• Compare the DSM criteria and use a transdiagnostic framework understanding for post-traumatic stress.
• Justify the rationale for using a transdiagnostic approach to the treatment of post-traumatic stress.
• Describe the role that shame plays in post-traumatic stress and therapeutic approaches to working with shame.
• Existential distress
• Treatment plans for demoralization and existential distress
• Psychedelic-assisted therapy for demoralization and existential distress
• Apply existential therapy, supportive and expressive therapy, and mindfulness to psychedelic-assisted therapy for clients with chronic and serious illness.
• Explain the difference between depression and demoralization for the purposes of treating existential distress.
• Substance use disorders
• Psychedelic-assisted therapy for substance use disorders
• Motivational enhancement therapy
• Relapse prevention
• Identify which psychedelic medicines have been used for psychedelic-assisted therapy in the treatment of substance use disorders.
• Describe key evidence-based literature supporting the use of psychedelic-assisted therapy in the treatment of substance use disorders.
• Demonstrate a rudimentary understanding of motivational interviewing and motivational enhancement therapy and how it relates to psychedelic-assisted therapy in the treatment of substance use disorders.
• Explain the importance of relapse prevention skills as an important part of the treatment of substance use disorders.
• Complex PTSD
• Life course stress theory
• Wrapping everything together
• Case conceptualization
• Recall PTSD diagnostic criteria and compare with Comlex PTSD criteria.
• Review transdiagnostic considerations involving traumatic stress.
• Describe life course theory as a framework that explicitly considers socioenvironmental factors into understanding client presentation and case conceptualization from a JEDI lens.
• Apply a case conceptualization framework which incorporate a biopsychosocial approach to transdiagnostic mental health assessment and treatment.
After the course, you’ll be able to
Determine the symptoms and appropriate treatments for the conditions presented.
Integrate different perspectives regarding assessment and treatment approaches applied to psychedelic-assisted therapy.
Discuss key psychedelic-assisted therapy research and proposed therapeutic mechanisms.
Apply best practices for preparation, medicine, and integration sessions.
Assess client’s suitability for treatment according to relative and absolute contraindications.
Identify potential challenges and risks associated with these disorders and limitations of psychedelic-assisted therapy as a brief intervention.
The continuing professional development program in no way promotes, condones, or facilitates illegal activity, and is strictly for educational and harm reduction purposes only. Please be aware that certain psychedelic substances still remain illegal in many jurisdictions, including Canada. This program and the contents of this website do not constitute medical advice, and are not a substitute for professional medical advice and treatment.
Yes, you will need to complete the following before registering:
- Fundamentals of Psychedelic-Assisted Therapy (8-week program)
- Familiarity and experience with motivational interviewing.
If you do not have this, please reach out to firstname.lastname@example.org for recommendations to support you.
Yes, once you complete 24 hours of training.
You will need to be able to commit to all the live sessions in order to receive a proof of completion certificate. Please email email@example.com if you have any special circumstances.
Yes, just be mindful of the time zones!
Please consult the Numinus Practitioner Training Policies for more information about our policies.
We’re happy to help. Send us an email at firstname.lastname@example.org